कोविड-19 वैक्सीन: गरीब देशों के लिए दाम महंगे, खुराक बहुत कम

40 साल बाद भी एड्स की कोई वैक्सीन नहीं बनी है, जिससे अफ्रीक…

रोगजनकों का डाटा शेयर करने की रणनीति से महामारियों में नहीं हुआ फायदा

इंडोनेशिया ने पक्षियों से जुड़े इंफ्लुएंजा को पैदा करने…

COVID-19 vaccines: African countries get very few doses at very high prices

Guinea, one of the lowest-income countries, has received just 25 doses 

Sharing pathogens but not the benefits during pandemics

Western nations and pharma companies have, for long, allegedly appropriated and taken thousands of pathogen specimens and data without permission …

Assault on open access to science in India

Elsevier, Wiley and American Chemical Society have pleaded in front of Delhi High Court that ISPs block Sci-Hub and Libgen websites in India

Wishing for a Jonas Salk in the age of COVID-19

The philosophy of the virologist who developed the vaccine for polio is clearly anathema to today’s drug researchers

COVID-19: The poor must wait years for the jab

Intellectual property rights can act as a barrier against wide access to vaccines, treatments for the novel coronavirus disease  

Who is really afraid of the TRIPS agreement? 

India has not shown the grit to fully use the inbuilt flexibilities in the WTO’s TRIPS pact to protect public health

Will a new and ‘improved’ WTO be in India’s interests

The World Trade Organization needs an overhaul, but the reform will leave even less space for developing nations

Bankruptcy of ideas and innovation: What India’s recent science & tech indicators show

Indians have shown little innovation over the decades. They are content to copy successful ideas from elsewhere or …

US officials urge to override Gilead patent

Most of US state attorney generals want the government to use its march-in-rights to license remdesivir to others

Remdesivir: Predatory pricing of an unproven drug

Gilead Science’s price for the remdesivir drug reveals a faulty patents system and skewed policies of the United States

Industry paid for IP seminars to train judges

Microsoft and Indian Music Industry funded FICCI to hold roundtable for Maharashtra judiciary; judges handling piracy cases special invitees

Dangers of a nationalist vaccine

In the time of COVID-19, the Indian government has shown an embarrassing readiness to cut corners by seeking to push through a vaccination by …

Smoke and mirrors on COVID-19 drugs?

In a brutal fight to corner the successful outcome of research, governments are openly using money power to grab the first rights to promising …

A promise of equitable access to all

WHO, pharma giants and governments have come together to provide access to all on COVID-19 therapies. But will WIPO allow this to happen?

A dirty US fight to control WIPO

China loses to Singapore in American smear campaign but the US will have to contend with an IP powerhouse

India’s proposed rules to curb web content to undercut digital freedom, privacy

Changes envisaged are far-reaching, making intermediaries accountable for content on their platforms; no longer eligible for safe harbour …

The great coronavirus drug hunt

A patent filed by Institute of Virology in Wuhan on cocktail of remdesivir and chloroquine raises some prickly questions 

ट्रंप का भारत दौरा: यह समझौता हुआ तो खत्म हो जाएगा सस्ती दवाओं का दौर

अमेरिकी राष्ट्रपति के भारत दौरे पर उनकी बौद्धिक संपदाओ�…

Beware of a deal with Trump

As the US president comes visiting to India there is worry about the demands he will make on intellectual property

The US takes on a drug giant

The US government's patent lawsuit against Gilead Sciences indicates it is tired of being milked by pharma companies

A Modi motto on innovation

A simplistic formulation ignores the reality of India's research environment and the constraint it faces

Cipla shows the way, again

The pioneer of inexpensive AIDS drugs made a paediatric medicine that will save thousands of children

India's withdrawal from RCEP a breather on many fronts

India's decision to pull out of RCEP means its policy on access to inexpensive drugs will not be under pressure